Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.

C. Araujo, John; C. Trudel, Géralyn; Saad, Fred; J. Armstrong, Andrew; Y. Yu, Evan; Bellmunt, Joaquim; Wilding, George; McCaffrey, John; Serrano, Sérgio; Б. Матвеев, В.; Efstathiou, Eleni; Oudard, Stéphane; J. Morris, Michael; Sizer, Bruce; J. Goebell, Peter; S. de Bono, Johann; Paliwal, Prashni; DURHAM, S; Cheng, Shinta; J. Logothetis, Christopher

doi:10.1200/jco.2013.31.6_suppl.lba8

Public

Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.

Published in Journal of Clinical Oncology • Feb 20, 2013

Authors:

John C. Araujo

Géralyn C. Trudel

Fred Saad

Abstract

LBA8 Background: SRC kinases may contribute to androgen independence of mCRPC.Dasatinib (DAS) inhibits tyrosine kinases including SRC kinases with preclinical evidence for antimetastatic activity, inhibition of osteoclast function in tumor microenvironment, and synergistic activity with docetaxel (D...

Subject

Medicine

Docetaxel

Dasatinib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!